Literature DB >> 12843740

Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L.

Ranajit Pal1, Brian Taylor, J Scott Foulke, Ruth Woodward, Michael Merges, Rob Praschunus, Andrew Gibson, Marvin Reitz.   

Abstract

The tat, rev, vpu, and env genes from the monocytotropic CCR5-dependent HIV-1 Ba-L isolate were substituted for homologous simian immunodeficiency virus (SIV) sequences in the SIV genome. The resultant SHIV (SHIV Ba-L) replicated in CCR5-positive PM-1 cells but not in CCR5-negative CEMX174 cells. Infection of HOS cells expressing different co-receptors showed SHIV Ba-L to be strictly CCR5-dependent. Infection of PM-1 cells and rhesus peripheral blood mononuclear cells (PBMCs) was highly sensitive to RANTES but not to SDF-1. Although SHIV Ba-L infected rhesus and pigtail macaques intravenously or rectally, plasma viremia was controlled after 3 weeks. After serial passage through 4 pigtails by blood and bone marrow transfer, virus from pigtail PBMCs had higher in vitro infectious titers on rhesus PBMCs and was efficiently transmitted vaginally in rhesus and cynomolgus macaques. Plasma viremia generally persisted longer than after infection with unpassaged virus but was eventually controlled with no significant decrease in CD4+ T-cell counts in peripheral blood. The envelope gene of SHIV Ba-L revealed a very little genetic drift during in vivo passage. SHIV Ba-L provides a potentially useful model for R5 HIV-1 infection of humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843740     DOI: 10.1097/00126334-200307010-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  29 in total

1.  Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.

Authors:  Rajeev Gautam; Yoshiaki Nishimura; Wendy R Lee; Olivia Donau; Alicia Buckler-White; Masashi Shingai; Reza Sadjadpour; Stephen D Schmidt; Celia C LaBranche; Brandon F Keele; David Montefiori; John R Mascola; Malcolm A Martin
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 2.  Animal models for microbicide studies.

Authors:  Ronald S Veazey; Robin J Shattock; Per Johan Klasse; John P Moore
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

3.  Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Amarendra Pegu; Ivelin S Georgiev; Ming Zeng; M Gordon Joyce; Zhi-Yong Yang; Sung-Youl Ko; Xuejun Chen; Stephen D Schmidt; Ashley T Haase; John-Paul Todd; Saran Bao; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

4.  Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Anderson Frank; David Worthylake; Hye-Kyung Chung; Patricia Polacino; Dean H Hamer; Cody P Coyne; Michael G Rosenblum; John W Marks; Gang Chen; Deborah Weiss; Victor Ghetie; Ellen S Vitetta; James E Robinson; Shiu-Lok Hu
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

5.  Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques.

Authors:  Yoshiaki Nishimura; Masashi Shingai; Ronald Willey; Reza Sadjadpour; Wendy R Lee; Charles R Brown; Jason M Brenchley; Alicia Buckler-White; Rahel Petros; Michael Eckhaus; Victoria Hoffman; Tatsuhiko Igarashi; Malcolm A Martin
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection.

Authors:  Daryl Humes; Sandra Emery; Elizabeth Laws; Julie Overbaugh
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

7.  Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Authors:  Christopher Sundling; Sijy O'Dell; Iyadh Douagi; Mattias N Forsell; Andreas Mörner; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

8.  Anti-HIV Passive Immunization: New Weapons in the Arsenal.

Authors:  Ruth M Ruprecht
Journal:  Trends Microbiol       Date:  2017-10-30       Impact factor: 17.079

9.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.

Authors:  Amarendra Pegu; Zhi-yong Yang; Jeffrey C Boyington; Lan Wu; Sung-Youl Ko; Stephen D Schmidt; Krisha McKee; Wing-Pui Kong; Wei Shi; Xuejun Chen; John-Paul Todd; Norman L Letvin; Jinghe Huang; Martha C Nason; James A Hoxie; Peter D Kwong; Mark Connors; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.